SCA
CORT icon

Spearhead Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

Spearhead Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-16,876
Closed -$334K – 204
2021
Q4 		$334K Buy
16,876
+276
+2% +$5.6K 0.04% 139
2021
Q3 		$327K Sell
16,600
-92
-0.6% -$1.93K 0.04% 142
2021
Q2 		$367K Buy
16,692
+2,487
+18% +$55.3K 0.05% 157
2021
Q1 		$338K Sell
14,205
-3,643
-20% -$97.3K 0.05% 135
2020
Q4 		$467K Buy
17,848
+364
+2% +$7.67K 0.07% 103
2020
Q3 		$304K Buy
17,484
+1,147
+7% +$18.3K 0.06% 131
2020
Q2 		$275K Buy
16,337
+3,219
+25% +$45.2K 0.06% 117
2020
Q1 		$156K Buy
+13,118
New +$162K 0.05% 97

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Spearhead Capital Advisors's CORT Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Corcept Therapeutics (CORT) in Q1 2022, closing a stake of 16,876 shares — an estimated $334K sold.

Spearhead Capital Advisors first reported a position in CORT in Q1 2020 and held it in 8 quarters. The position peaked at $467K in Q4 2020. 228 funds tracked by Wall St. Rank hold CORT as of Q1 2022.

  • Spearhead Capital Advisors reported no remaining Corcept Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 16,876 Corcept Therapeutics shares in Q1 2022, an estimated $334K.
  • Spearhead Capital Advisors first reported a position in Corcept Therapeutics in Q1 2020 and held it in 8 quarters.
  • Spearhead Capital Advisors's Corcept Therapeutics position peaked at $467K in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.